NDA 012750 · Bausch
Librax
Chlordiazepoxide Hydrochloride, Clidinium Bromide · Oral
Last checked: Nov 20, 2026Latest source record: Jan 13, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1966
Sep 1, 1966
Approved uses
1
Original approval plus efficacy supplements
Registered trials
6
2 Phase 3, 0 recruiting
FAERS reports
1,925
1,089 serious, 68 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: RISKS FROM CONCOMITANT USE WITH OPIOIDS; ABUSE, MISUSE, AND ADDICTION; and DEPENDENCE AND WITHDRAWAL REACTIONS • Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of these drugs in patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Follow patients for signs and symptoms of respiratory depression and sedation (see WARNINGS and PRECAUTIONS and PRECAUTIONS , Drug Interactions ). • The use of benzodiazepines, including chlordiazepoxide hydrochloride, a component of Librax, exposes users to risks of abuse, misuse, and addiction, which can lead to overdose or death. Abuse and misuse of benzodiazepines commonly involve concomitant use of other medications, alcohol, and/or illicit substances, which is associated with an...
What it is approved for
From the label in effect Jan 13, 2023.
INDICATIONS AND USAGE: Librax is indicated to control emotional and somatic factors in gastrointestinal disorders. Librax may also be used as adjunctive therapy in the treatment of peptic ulcer and in the treatment of the irritable bowel syndrome (irritable colon, spastic colon, mucous colitis) and acute enterocolitis.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Sep 1, 1966 Original approval · Type 4 - New Combination
1 products under this application
- LIBRAX · CHLORDIAZEPOXIDE HYDROCHLORIDE 5MG; CLIDINIUM BROMIDE 2.5MG · CAPSULE, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Chlordiazepoxide" as an intervention, any sponsor and status, largest first.
- Outpatient Treatment of Alcohol Withdrawal SyndromePivotal-lookingCompleted
Hvidovre University HospitalAcademic, hospital or other
NCT00136617 · 165 participants · Start Aug 2003 · Primary completion Jul 2006
Drug: chlordiazepoxide · For: Alcoholism; Alcohol Withdrawal
Sites: Hvidovre, Denmark
- A Study of the Use of Combination of Anti-cholinergic and Minor Tranquilliser in the Treatment of Non-cardiac Chest Pain - a Double Blind Placebo Controlled StudyPivotal-lookingStatus unknown
Hospital Authority, Hong KongGovernment (non-federal)
NCT00516854 · 100 participants (planned) · Start Jun 2002
Drug: chlordiazepoxide 5 mg, clidinium 2.5 mg, twice daily · For: Chest Pain
Sites: Hong Kong, China
Mayo ClinicAcademic, hospital or other
NCT03012815 · 88 participants · Start Feb 1, 2017 · Primary completion Mar 1, 2021
Drug: Gabapentin; Benzodiazepines and 1 more · For: Alcohol Withdrawal Syndrome
Sites: Rochester, Minnesota
- Pioglitazone as an Adjunct for Moderate to Severe Depressive DisorderPivotal-lookingCompleted
Tehran University of Medical SciencesAcademic, hospital or other
NCT01109030 · 50 participants · Start Apr 2010 · Primary completion Oct 2011
Drug: Pioglitazone+Citalopram+Chlordiazepoxide; Placebo+ Citalopram+ Chlordiazepoxide · For: Major Depressive Disorder
Sites: Tehran, Iran
Fayoum UniversityAcademic, hospital or other
NCT06731101 · 46 participants · Start Jan 15, 2025 · Primary completion Dec 10, 2025
Drug: Bupivacaine + Lidocaine +dexamethasone; Tryptizole + Librax · For: Palmar Hyperhidrosis
Sites: Al Fayyum, Egypt
VA Salt Lake City Health Care SystemFederal agency
NCT01573052 · 26 participants · Start Mar 2004 · Primary completion Aug 2010
Drug: Chlordiazepoxide; Gabapentin · For: Alcohol Withdrawal
Sites: Salt Lake City, Utah
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- diarrhoea182
- nausea182
- fatigue169
- drug ineffective141
- pain132
- headache120
- abdominal pain112
- dizziness108
- vomiting98
- asthenia97
- arthralgia95
- weight decreased95
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 81 |
| 2005 | 81 |
| 2006 | 60 |
| 2007 | 74 |
| 2008 | 75 |
| 2009 | 77 |
| 2010 | 84 |
| 2011 | 98 |
| 2012 | 122 |
| 2013 | 108 |
| 2014 | 91 |
| 2015 | 194 |
| 2016 | 185 |
| 2017 | 131 |
| 2018 | 91 |
| 2019 | 59 |
| 2020 | 51 |
| 2021 | 60 |
| 2022 | 45 |
| 2023 | 49 |
| 2024 | 57 |
| 2025 | 26 |
| 2026 | 26 |
Recalls
1 FDA enforcement reports for this application.
Apr 18, 2015 · Class III · Terminated
Failed Impurities/Degradation Specifications
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Librax (Chlordiazepoxide/Clidinium Br)
2024 spending
$2.4M
Beneficiaries
351
1,011 claims
Per beneficiary
$6,821
$14.81 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $6,601,655 |
| 2021 | $5,018,637 |
| 2022 | $3,680,666 |
| 2023 | $3,034,242 |
| 2024 | $2,394,191 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Comparative efficacy and safety of pharmacotherapies for alcohol withdrawal: a systematic review and network meta-analysis.
Bahji A, Bach P, Danilewitz M, et al. · Addiction 2022 · Systematic Review, Network Meta-Analysis
- A prospective, randomized, trial of phenobarbital versus benzodiazepines for acute alcohol withdrawal.
Hendey GW, Dery RA, Barnes RL, et al. · Am J Emerg Med 2011 · Comparative Study, Randomized Controlled Trial
- Baclofen for alcohol withdrawal.
Liu J, Wang LN · Cochrane Database Syst Rev 2017 · Systematic Review
- Baclofen for alcohol withdrawal.
Liu J, Wang LN · Cochrane Database Syst Rev 2019 · Meta-Analysis, Systematic Review
- Benzodiazepines for alcohol withdrawal.
Amato L, Minozzi S, Vecchi S, et al. · Cochrane Database Syst Rev 2010 · Meta-Analysis, Systematic Review
- Anticonvulsants for alcohol withdrawal.
Minozzi S, Amato L, Vecchi S, et al. · Cochrane Database Syst Rev 2010 · Meta-Analysis, Systematic Review
Sponsor: Bausch
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.